Track topics on Twitter Track topics that are important to you
Novoeight (turoctocog alfa) is a recombinant coagulation factor VIII.
The FDA approved Novoeight® for use in adults and children with haemophilia A for:
Novoeight® has been studied in the guardian™ clinical programme; one of the largest and most comprehensive pre-registration clinical trial programmes in the field of haemophilia therapy with more than 210 severe haemophilia A patients. In the completed trials Novoeight® demonstrated good efficacy in preventing and treating bleeds and had no confirmed inhibitor development, and all patients in the surgery trial were treated effectively. Novoeight® will be launched with the newly introduced prefilled device, MixPro®.
For further information: http://www.novonordisk.com/